Naproxen Sodium Articles
Takeda and Shionogi announce US acquisitions
28 May 2009
Shionogi set to buy Victory for $150M
19 May 2009
Victory Pharma closes $45M equity financing
16 March 2009
Watson and Elan in naproxen settlement
16 March 2009
Pozen shares drop 28% on Treximet challenge
27 October 2008
Court rules against Watson on Naprelan patent
18 August 2008
$20M GSK milestone for Pozen
5 May 2008
GSK's Treximet receives FDA approval
21 April 2008
Trexima receives second approvable letter
13 August 2007
Pozen submits full Trexima response to FDA
20 November 2006
Early Trexima use cuts migraine symptoms
2 October 2006
Migraine combo-therapy evaluated
3 July 2006
FDA delays decision on Pozen/GSK's Trexima
19 June 2006
Pozen's MT 100 approved in UK
5 December 2005
FDA sets date for review of Pozen's drug
11 July 2005
Bayer submits naproxen safety profile to FDA
14 February 2005
Recordati obtains new drug in Spain
5 July 2004
Pozen's MT 100 "not approvable"
7 June 2004
Pozen/GSK's Trexima enters Phase III
24 May 2004
US FDA to educate about OTC painkillers
2 February 2004
FDA rejects Pozen's lead migraine product
27 October 2003
Pozen files NDA in the USA for MT 100
11 August 2003
USA's FTC probing Elan, Skye and AstraZeneca
10 March 2003
Pozen to file requested data on MT 100 in 2002
20 September 2001
Pozen completes Ph III program for MT 100
21 February 2001
Pozen rocked by delay to migraine drug
30 January 2001
ICN buys rights to NSAIDs from Roche
9 January 2001
Healthy full-year results for many US pharmaceutical companies
27 January 2000
Hefty increase in 3rd qtr revenues at Elan
26 October 1999
New Evidence Supports Vioxx GI Safety
15 December 1998
Elan Regains Naprelan And Verelan Rights
24 September 1998
Andrx Submits ANDA For Bioequivalent Drugs
23 September 1998
SkyePharma Files ANDA For Naproxen
30 July 1998
American Home Pharma Sales Up 7% For 2nd Qtr
22 July 1998
US Quarterly Financial Results Round-Up
23 April 1998
Strong Growth At Elan Corp, Net Income Up 51%
9 February 1998
Strong Growth For US Drug Firms In 1997
28 January 1998
FDA Warning On OTC Analgesics
20 November 1997
Sales Slip At American Home Products
5 May 1997
FDA Approves Pharmaceutical Formulations' Naproxen
24 April 1997
Elan Corp Takes One-Time Charge At Nine Months
10 February 1997
Elan Corp's 2nd Quarter Reflects Athena Acquistion
4 November 1996
Net profits Up Over 50% At Elan Corp
5 August 1996
Single-Digit Profits Growth For B-MS And W-L
5 August 1996
Patent Expiries Set To Drive Generics Boom
22 July 1996
Wyeth-Ayerst Launches Naprelan
10 June 1996
Strong Year-End For Elan Corporation
13 May 1996
Earnings Growth In Excess of 25% At Elan?
15 April 1996
Elan Corporation Sees Net Profits Rise 28%
22 January 1996
Elan's Naprelan: news
22 January 1996
Elan gets new Naprelan approval
15 January 1996
Generics: A Passage Through Time
4 September 1995
Procter & Gamble To Expand Drugs Business
14 August 1995
Elan/Wyeth-Ayerst agreement to market Naprelan
31 July 1995
US Sales of Generic Drugs Up 29% In 1994, Says IMS
17 July 1995
Rugby Group gets approval for gemibrozil
19 June 1995
Mylan Receives Two Product Approvals
26 September 1994
WHAT FUTURE FOR STERLING HEALTH
4 July 1994
THE CHANGING US ANALGESIA MARKET
27 June 1994
US FDA URGED TO ACCEPT FOREIGN DATA FOR OTCS
27 June 1994
SYNTEX' 3rd QTR NET PLUNGES 45%
20 June 1994
SYNTEX' 3rd QTR NET PLUNGES 45%
20 June 1994
BUY RECOMMENDATION FOR TEVA STOCK
11 April 1994
GENERIC COMPETITION HITS SYNTEX
7 March 1994
BRAND EQUITY IN THE OTC DRUG MARKET
7 February 1994
CIBA LAUNCHES CATAFLAM NSAID IN USA
31 January 1994
SYNTEX CHIEF SPEAKS ON PRODUCT PROSPECTS
24 January 1994
FIRST OTC NAPROXEN CLEARED FOR SALE
17 January 1994
SYNTEX EXPECTS PATENT EXPIRY EFFECTS
13 December 1993
NAPROXEN OTC SWITCH REJECTION EXAMINED
13 December 1993
MUSCULOSKELETAL MARKET TO DECLINE
6 December 1993
103% NET INCOME RISE FOR ISRAEL's TEVA
22 November 1993
HAMILTON RECEIVES ANDA APPROVAL
13 September 1993
MYLAN'S NAPROXEN APPROVED IN USA
13 September 1993
TEVA CORPORATE DEVELOPMENTS
5 July 1993
SYNTEX PROFITS HIT BY RESTRUCTURING
7 June 1993
RPSGB CANDIDATES FOR POM-TO-P SWITCHING
2 November 1992
Showing 1-87 of 87 articles
- 1
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- AstraZeneca plans to move three cancer drug candidates into Ph III
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Merck Serono Ph III trial of L-BLP25 fails endpoint in NSCLC
